Publications & Testimony

Items: 831 — 840


Apr 22, 2021

Commentary: Ending Capital Punishment is a Core Component of Reconceptualizing Public Safety’ in an Era of Punitive Excess

As the United States under­goes an awak­en­ing on racial injus­tices in polic­ing and the judi­cial process, com­men­ta­tors and pub­lic pol­i­cy advo­cates are call­ing for a reimag­in­ing of pub­lic safe­ty and crim­i­nal pun­ish­ment that rejects the reflex­ive impo­si­tion of harsh pun­ish­ment as an instru­ment of social…

Read More

Apr 21, 2021

Amnesty International Global Report: Executions Worldwide Fewest in a Decade, Death Sentences Fall More Than One Third in 2020

Fewer exe­cu­tions were car­ried out across the world in 2020 than at any time in a decade and new death sen­tences fell by more than a third, accord­ing to a new report by Amnesty International. It was the third con­sec­u­tive year in which con­firmed exe­cu­tions reached a 10-year low, and the sixth year in a row in which con­firmed exe­cu­tions declined, Amnesty…

Read More

Apr 15, 2021

NEWS BRIEF — Tennessee Legislative Committees Approve Intellectual Disability Bill

On April 14, 2021, com­mit­tees in both cham­bers of the Tennessee leg­is­la­ture vot­ed to advance bills that would cre­ate a legal mech­a­nism for death-row pris­on­ers to chal­lenge their death sen­tences on the grounds that they have intel­lec­tu­al dis­abil­i­ty. The leg­is­la­tion would close a loop­hole in Tennessee law that denies pris­on­ers whose con­vic­tions became final before the U.S. Supreme Court barred the exe­cu­tion of indi­vid­u­als with intel­lec­tu­al dis­abil­i­ty any oppor­tu­ni­ty to present…

Read More

Apr 15, 2021

Arizona DoC Paid $1.5 Million for Execution Drugs While Facing a Budget Crisis

At a time in which the Arizona Department of Corrections is fac­ing crit­i­cism for crum­bling infra­struc­ture, sub­stan­dard med­ical care, and under­staffing, the depart­ment has spent $1.5 mil­lion to pur­chase the lethal-injec­tion drug pen­to­bar­bi­tal from an undis­closed source. The exor­bi­tant price, experts say, is a func­tion of the ques­tion­able use of the drug for non-med­ical pur­pos­es and the secre­tive nature of the…

Read More